Novigrel (Clopidogrel Besilate)

Clopidogrel Besilate, the active ingredient in Novigrel, is an antiplatelet agent presented as an oral tablet for oral use. It is used to reduce the risk of atherothrombotic events in patients with recent myocardial infarction, stroke, acute coronary syndrome, or who have undergone percutaneous coronary intervention.

GNH USA supplies Novigrel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novigrel, a P2Y12 receptor antagonist, is employed in several cardiovascular conditions to inhibit platelet aggregation.

- Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. - Post‑percutaneous coronary intervention (PCI): prevents stent thrombosis and recurrent ischemic events. - Established peripheral arterial disease, recent myocardial infarction or stroke: lowers incidence of atherothrombotic events.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bleeding: mild to moderate gastrointestinal or mucosal bleeding. - Bruising: increased tendency to develop bruises. - Diarrhea: loose stools, often transient. - Nausea: mild, occasional nausea. - Headache: intermittent headache. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Severe bleeding: intracranial hemorrhage or life‑threatening gastrointestinal bleed. - Thrombotic thrombocytopenic purpura (TTP): rare, potentially fatal microangiopathic disorder. - Allergic reactions: anaphylaxis or severe hypersensitivity. - Hepatotoxicity: elevated liver enzymes in rare cases. - Hemolytic anemia: uncommon but serious. - Thrombocytopenia: marked reduction in platelet count.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients closely.

- Assess bleeding risk: review history of hemorrhage, ulcers or coagulopathy. - Monitor platelet function: consider laboratory testing in high‑risk patients. - Avoid in active pathological bleeding: contraindicated during uncontrolled bleeding episodes. - Caution in hepatic impairment: dose adjustment may be required. - Discontinue before surgery: stop according to procedural guidelines. - Store at below 25°C: keep in the original pack, protect from moisture.

Clopidogrel Besilate may interact with several drug classes, influencing bleeding risk or antiplatelet efficacy.

Major Interactions (Avoid): - Concurrent use with oral anticoagulants (e.g., warfarin): markedly increased bleeding risk. - Combination with strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): reduced conversion to active metabolite, diminishing antiplatelet effect. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Co‑administration with proton pump inhibitors (e.g., pantoprazole): possible interaction, monitor clinical response. - Concurrent use with selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency, observe for signs. - Combination with other antiplatelet agents (e.g., aspirin): additive effect on bleeding, require careful monitoring.